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Background
NK cells play a pivotal role in the innate immunity and
patrol various tissues, including mucosal sites, the portal
of entry of HIV. We recently reproduced in the SIV
mac251- rhesus macaque (RM) model the limited protec-
tion reported in the RV144 HIV vaccine trial in humans
(32% protection from HIV acquisition), using similar
vaccines (ALVAC-SIV & gp120).
Methods
In here, we immunized, by the intramuscular route, 6
RM with 108 PFU of ALVAC-SIV at weeks, 0 (V0), 4
(V2), and with both ALVAC SIV and the SIVgp120
envelope proteins, adjuvanted with ALUM at week 12
(V3) and 24 (V4) and analyzed the profile of gene
expression at 24 hours after each vaccination. In paral-
lel, we studied the phenotypical and functional changes
in the NK cell subsets after vaccination by multi para-
metric flow cytometry.
Results
Microarray analysis in the PBMC after V1 and V2
showed the up regulation of anti viral (MX1, HERC-5)
and IFN responsive genes and a down regulation of pro-
inflammatory genes. Significant alteration in the gene
expression profile was also observed after the gp120/
Alum boost (V3). Interestingly, NK cells associated
genes were up regulated after V3 vaccination. These
finding paralleled our results observed by FACS analysis
that demonstrated an increased frequency of NK22 cells
at mucosal sites. These NK22 cells expressed CCR6 (a
gut homing marker) and are thought to play a role in
mucosal immunity. Similarly, vaccination also increased
the frequency of NKG2A+ cells that were either cyto-
toxic (CD107a+) or cytokine producing (IFNg+).
Conclusion
Thus, the ALVAC SIV/gp120 vaccine regimen induces a
significant activation of NK cells and other innate
immune responses. Given that this vaccine platform has
conferred some degree of protection from HIV infection
in humans, understanding the role of innate immunity
in protection from SIVmac251 may guide our effort in
the development of novel vaccine strategies against HIV.
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